FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016086054> ?p ?o ?g. }

• W2016086054 endingPage "1000" @default.
• W2016086054 startingPage "991" @default.
• W2016086054 abstract "Several studies have demonstrated differences in omega-3 fatty acid composition in plasma and in erythrocyte membranes in patients with attention-deficit/hyperactivity disorder (ADHD) compared with unaffected controls. Omega-3 fatty acids have anti-inflammatory properties and can alter central nervous system cell membrane fluidity and phospholipid composition. Cell membrane fluidity can alter serotonin and dopamine neurotransmission. The goal of this meta-analysis was to examine the efficacy of omega-3 fatty acid supplementation in children with ADHD.PubMed was searched for randomized placebo-controlled trials examining omega-3 fatty acid supplementation in children with ADHD symptomatology. The primary outcome measurement was standardized mean difference in rating scales of ADHD severity. Secondary analyses were conducted to determine the effects of dosing of different omega-3 fatty acids in supplements.Ten trials involving 699 children were included in this meta-analysis. Omega-3 fatty acid supplementation demonstrated a small but significant effect in improving ADHD symptoms. Eicosapentaenoic acid dose within supplements was significantly correlated with supplement efficacy. No evidence of publication bias or heterogeneity between trials was found.Omega-3 fatty acid supplementation, particularly with higher doses of eicosapentaenoic acid, was modestly effective in the treatment of ADHD. The relative efficacy of omega-3 fatty acid supplementation was modest compared with currently available pharmacotherapies for ADHD such as psychostimulants, atomoxetine, or α(2) agonists. However, given its relatively benign side-effect profile and evidence of modest efficacy, it may be reasonable to use omega-3 fatty supplementation to augment traditional pharmacologic interventions or for families who decline other psychopharmacologic options." @default.
• W2016086054 created "2016-06-24" @default.
• W2016086054 creator A5018495836 @default.
• W2016086054 creator A5060512263 @default.
• W2016086054 date "2011-10-01" @default.
• W2016086054 modified "2023-09-27" @default.
• W2016086054 title "Omega-3 Fatty Acid Supplementation for the Treatment of Children With Attention-Deficit/Hyperactivity Disorder Symptomatology: Systematic Review and Meta-Analysis" @default.
• W2016086054 cites W1621771198 @default.
• W2016086054 cites W1895462365 @default.
• W2016086054 cites W1965928582 @default.
• W2016086054 cites W1966648066 @default.
• W2016086054 cites W1972030555 @default.
• W2016086054 cites W1977729556 @default.
• W2016086054 cites W1979122474 @default.
• W2016086054 cites W1980568154 @default.
• W2016086054 cites W1981736255 @default.
• W2016086054 cites W1992847121 @default.
• W2016086054 cites W1996091936 @default.
• W2016086054 cites W1996888494 @default.
• W2016086054 cites W2003751213 @default.
• W2016086054 cites W2006058627 @default.
• W2016086054 cites W2011464438 @default.
• W2016086054 cites W2013810982 @default.
• W2016086054 cites W2015709747 @default.
• W2016086054 cites W2016903803 @default.
• W2016086054 cites W2018883062 @default.
• W2016086054 cites W2027225253 @default.
• W2016086054 cites W2029212126 @default.
• W2016086054 cites W2031385454 @default.
• W2016086054 cites W2032014208 @default.
• W2016086054 cites W2039178589 @default.
• W2016086054 cites W2064375795 @default.
• W2016086054 cites W2071373294 @default.
• W2016086054 cites W2096024129 @default.
• W2016086054 cites W2097882979 @default.
• W2016086054 cites W2105182245 @default.
• W2016086054 cites W2109279406 @default.
• W2016086054 cites W2110112904 @default.
• W2016086054 cites W2111324366 @default.
• W2016086054 cites W2111614110 @default.
• W2016086054 cites W2113574456 @default.
• W2016086054 cites W2121921516 @default.
• W2016086054 cites W2125555008 @default.
• W2016086054 cites W2132025144 @default.
• W2016086054 cites W2140513029 @default.
• W2016086054 cites W2145076716 @default.
• W2016086054 cites W2145336940 @default.
• W2016086054 cites W2150436158 @default.
• W2016086054 cites W2157823046 @default.
• W2016086054 cites W2166577179 @default.
• W2016086054 cites W42478219 @default.
• W2016086054 doi "https://doi.org/10.1016/j.jaac.2011.06.008" @default.
• W2016086054 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3625948" @default.
• W2016086054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21961774" @default.
• W2016086054 hasPublicationYear "2011" @default.
• W2016086054 type Work @default.
• W2016086054 sameAs 2016086054 @default.
• W2016086054 citedByCount "347" @default.
• W2016086054 countsByYear W20160860542012 @default.
• W2016086054 countsByYear W20160860542013 @default.
• W2016086054 countsByYear W20160860542014 @default.
• W2016086054 countsByYear W20160860542015 @default.
• W2016086054 countsByYear W20160860542016 @default.
• W2016086054 countsByYear W20160860542017 @default.
• W2016086054 countsByYear W20160860542018 @default.
• W2016086054 countsByYear W20160860542019 @default.
• W2016086054 countsByYear W20160860542020 @default.
• W2016086054 countsByYear W20160860542021 @default.
• W2016086054 countsByYear W20160860542022 @default.
• W2016086054 countsByYear W20160860542023 @default.
• W2016086054 crossrefType "journal-article" @default.
• W2016086054 hasAuthorship W2016086054A5018495836 @default.
• W2016086054 hasAuthorship W2016086054A5060512263 @default.
• W2016086054 hasBestOaLocation W20160860542 @default.
• W2016086054 hasConcept C118552586 @default.
• W2016086054 hasConcept C126322002 @default.
• W2016086054 hasConcept C142724271 @default.
• W2016086054 hasConcept C168563851 @default.
• W2016086054 hasConcept C19038510 @default.
• W2016086054 hasConcept C204787440 @default.
• W2016086054 hasConcept C27081682 @default.
• W2016086054 hasConcept C2776091944 @default.
• W2016086054 hasConcept C2777112843 @default.
• W2016086054 hasConcept C2777171753 @default.
• W2016086054 hasConcept C2778781522 @default.
• W2016086054 hasConcept C2780783007 @default.
• W2016086054 hasConcept C3017514745 @default.
• W2016086054 hasConcept C543025807 @default.
• W2016086054 hasConcept C55493867 @default.
• W2016086054 hasConcept C71924100 @default.
• W2016086054 hasConcept C86803240 @default.
• W2016086054 hasConcept C98274493 @default.
• W2016086054 hasConceptScore W2016086054C118552586 @default.
• W2016086054 hasConceptScore W2016086054C126322002 @default.
• W2016086054 hasConceptScore W2016086054C142724271 @default.
• W2016086054 hasConceptScore W2016086054C168563851 @default.
• W2016086054 hasConceptScore W2016086054C19038510 @default.
• W2016086054 hasConceptScore W2016086054C204787440 @default.

• next